This lawsuit asserts that Defendants violated certain state antitrust, consumer protection, and unjust enrichment laws in the United States, harming competition and causing class members to overpay for Suboxone. Defendants deny that they violated any laws.

All persons or entities who purchased and/or paid for some or all of the purchase price for Co-Formulated Buprenorphine/Naloxone (Suboxone and/or its AB-rated generic equivalent) in any form, for consumption by themselves, their families or their members, employees, plan participants, beneficiaries or insureds in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and District of Columbia between December 22, 2011 and August 21, 2023.

The Settlement provides for Indivior’s payment of $30 million into a Settlement Fund for distribution to End Payor Class members submitting valid claim forms, attorneys’ fees, the expenses of litigation (including costs of Notice), and service awards to the named Plaintiffs, all of which is subject to final approval by the Court. The Court has scheduled a hearing (the “Fairness Hearing”) to consider whether to grant such final approval. The Fairness Hearing is scheduled for October 19, 2023, at 1:30 p.m., before Judge Mitchell S. Goldberg at the James A. Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106.

DO NOTHING If you are a member of the End Payor Class and want to remain a member of the End Payor Class, you are not required to do anything. To recover anything, however, you must submit a Claim Form as described immediately below. You will be bound by any decision of the Court in this lawsuit, including rulings on the Settlement.
SUBMIT A CLAIM FORM If you did not exclude yourself from the End Payor Class prior to the April 17, 2022 deadline and believe you are a End Payor Class Member, and want to participate in the distribution of the Net Settlement Fund, you will need to complete and return a Claim Form to obtain a share of the Settlement Fund. The Claim Form, and information on how to submit it, are available on the File A Claim tab above. Consumer identities will not be made public during any part of the claims process. Claim Forms must be postmarked (if mailed) or received (if submitted online) on or before February 17, 2024.
EXCLUDE YOURSELF FROM THE END PAYOR CLASS This option allows you to exclude yourself from the End Payor Class and retain the right to file a lawsuit against Indivior asserting the claims relating to the allegations in this case. If you exclude yourself, you will not share in any money from the Settlement. The exclusion deadline is October 12, 2023. Consumer identities will not be made public during any part of the exclusion process.
OBJECT TO THE SETTLEMENT OR SPEAK AT THE FAIRNESS HEARING If you object to all or any part of the Settlement, request for attorneys’ fees, reimbursement of expenses, or service awards to the class representatives, or desire to speak in person at the Fairness Hearing, you must file a written letter of objection and/or a notice of intention to speak along with a summary statement with the Court and with Co-Lead Counsel and counsel for the Defendant by October 5, 2023. Consumer identities will not be made public without consent during the objection process.
GET MORE INFORMATION If you would like more information about the lawsuit, you can review the complete Notice and FAQ on the tab above and send questions to the Settlement Administrator and/or Co-Lead Counsel. Their information is located on the Contact Information tab above.